Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.